Savant Capital LLC Buys 236 Shares of McKesson Co. (NYSE:MCK)

Savant Capital LLC boosted its stake in McKesson Co. (NYSE:MCK) by 2.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,903 shares of the company’s stock after buying an additional 236 shares during the period. Savant Capital LLC’s holdings in McKesson were worth $4,122,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in MCK. Commonwealth Equity Services LLC boosted its holdings in shares of McKesson by 2.1% during the 3rd quarter. Commonwealth Equity Services LLC now owns 61,484 shares of the company’s stock valued at $26,737,000 after buying an additional 1,268 shares in the last quarter. Cambridge Investment Research Advisors Inc. increased its stake in shares of McKesson by 42.0% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 21,769 shares of the company’s stock valued at $9,466,000 after purchasing an additional 6,438 shares in the last quarter. Kingswood Wealth Advisors LLC bought a new position in shares of McKesson during the third quarter valued at approximately $217,000. Mission Wealth Management LP boosted its position in shares of McKesson by 2.5% in the 3rd quarter. Mission Wealth Management LP now owns 1,461 shares of the company’s stock worth $635,000 after purchasing an additional 35 shares in the last quarter. Finally, Dakota Wealth Management boosted its holdings in McKesson by 24.2% in the third quarter. Dakota Wealth Management now owns 1,290 shares of the company’s stock worth $561,000 after acquiring an additional 251 shares in the last quarter. Hedge funds and other institutional investors own 85.07% of the company’s stock.

Analysts Set New Price Targets

MCK has been the subject of several analyst reports. Argus raised their price target on shares of McKesson from $510.00 to $570.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. StockNews.com upgraded shares of McKesson from a “buy” rating to a “strong-buy” rating in a research note on Thursday, April 25th. Morgan Stanley increased their price objective on shares of McKesson from $522.00 to $548.00 and gave the company an “overweight” rating in a research report on Monday, April 15th. Citigroup increased their price target on McKesson from $575.00 to $620.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Mizuho raised their price objective on shares of McKesson from $450.00 to $505.00 and gave the stock a “neutral” rating in a report on Friday, February 9th. Two analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $536.71.

McKesson Price Performance

Shares of NYSE MCK opened at $531.21 on Thursday. McKesson Co. has a 1 year low of $352.34 and a 1 year high of $544.81. The firm has a fifty day moving average price of $529.73 and a 200-day moving average price of $491.30. The stock has a market cap of $69.81 billion, a PE ratio of 24.07, a price-to-earnings-growth ratio of 1.43 and a beta of 0.45.

McKesson (NYSE:MCK) last announced its quarterly earnings results on Wednesday, February 7th. The company reported $7.74 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.05 by $0.69. McKesson had a net margin of 0.99% and a negative return on equity of 262.63%. The company had revenue of $80.90 billion for the quarter, compared to the consensus estimate of $77.93 billion. During the same period in the previous year, the firm posted $6.90 EPS. McKesson’s revenue for the quarter was up 14.8% compared to the same quarter last year. On average, research analysts expect that McKesson Co. will post 27.59 EPS for the current year.

McKesson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, July 1st. Shareholders of record on Monday, June 3rd will be paid a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 0.47%. The ex-dividend date of this dividend is Friday, May 31st. McKesson’s payout ratio is 11.24%.

Insider Transactions at McKesson

In related news, EVP Leann B. Smith sold 186 shares of the business’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $496.00, for a total value of $92,256.00. Following the sale, the executive vice president now owns 1,511 shares in the company, valued at $749,456. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Brian S. Tyler sold 3,473 shares of the company’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $524.55, for a total transaction of $1,821,762.15. Following the sale, the chief executive officer now directly owns 43,445 shares in the company, valued at approximately $22,789,074.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Leann B. Smith sold 186 shares of McKesson stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $496.00, for a total value of $92,256.00. Following the completion of the transaction, the executive vice president now owns 1,511 shares of the company’s stock, valued at approximately $749,456. The disclosure for this sale can be found here. Insiders own 0.21% of the company’s stock.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.